Using Frugal Business Model, Orphagen Pharmaceuticals Targets Orphan Receptors

Published: Jun 13, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The decline of venture capital investments in life sciences startups has provoked a lot of angst in the U.S., with many experts predicting a shortage of new drugs for the pharmaceutical product pipeline. Life sciences startups typically require hundreds of millions of dollars before they can show that an experimental drug might work in clinical trials with real patients. But San Diego’s Orphagen Pharmaceuticals runs against the conventional wisdom. As a case study in frugality, Orphagen has survived as an independent drug discovery company for over a decade, scraping by on grants and one crucial pharmaceutical partnership while enduring a mixed bag of challenges, risks, battles, and rewards

Help employers find you! Check out all the jobs and post your resume.

Back to news